Kentucky Bioprocessing LLC (KBP) and Bayer Innovation GmbH, a subsidiary of German pharmaceutical giant Bayer AG, are collaborating to develop a facility at KBP’s Owensboro plant for the production service of biopharmaceuticals. Based on Bayer’s proprietary magnICON® technology, plant-made pharmaceutical proteins and other high-value products will be produced in tobacco plants on commercial scale. KBP is investing $2 to $3 million to expand the partnership with Bayer and will adapt its existing facility for the installation of an automated system to accommodate production.
-
Share This!
Owensboro
November 1, 2008
342 Views
You may also like
Popular Stories
UofL Rugby wins D1 national championship
April 30, 2024
Lexington breaks ground on its first river park
May 1, 2024
The Lane Report
- VisitLEX recruits US Sports Congress event for 2025
- Louisville-based Climavision acquires Intersphere for AI-powered forecasts
- Lexington breaks ground on its first river park
- BE NKY Growth Partnership a Mac Conway Award winner
- National Corvette Museum giving military vets free admission
- Kentucky small businesses being recognized at State Capitol
- Lake Cumberland Wound Care recognized as a Healogics Center of Distinction
- VisitLEX celebrates history horse racing at Thursday Night LIVE
- Blue Note Bourbon pours Platinum at 2024 San Francisco Spirits
- LG&E and KU pursuing opportunities to add renewable energy
Add Comment